Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zovegalisib - Relay Therapeutics

Next Previous
Drug Profile

Zovegalisib - Relay Therapeutics

Alternative Names: RLY-2608

Latest Information Update: 26 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Relay Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Lymphatic disorders; Vascular malformations
  • Phase I/II Solid tumours

Most Recent Events

  • 16 Mar 2026 Updated pharmacokinetics, efficacy and adverse events data from the phase I/II ReDiscover trial in Solid tumours and Breast cancer released by Relay Therapeutics
  • 03 Feb 2026 Zovegalisib receives Breakthrough Therapy status for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease, Recurrent, Inoperable/Unresectable) in USA
  • 12 Dec 2025 Efficacy and adverse events data from the phase I ReDiscover trial in Solid tumours released by Relay Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top